Published in Nat Genet on May 01, 1995
Non-ATG-initiated translation directed by microsatellite expansions. Proc Natl Acad Sci U S A (2010) 3.58
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther (2005) 2.47
Differences in duration of Huntington's disease based on age at onset. J Neurol Neurosurg Psychiatry (1999) 1.63
Huntingtin-HAP40 complex is a novel Rab5 effector that regulates early endosome motility and is up-regulated in Huntington's disease. J Cell Biol (2006) 1.55
Poly-L-glutamine forms cation channels: relevance to the pathogenesis of the polyglutamine diseases. Biophys J (2000) 1.53
Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci U S A (1999) 1.30
Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci (2014) 1.27
Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features. J Neurochem (2010) 1.25
Repeat-associated non-ATG (RAN) translation in neurological disease. Hum Mol Genet (2013) 1.20
Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease. EMBO J (2010) 1.19
Neuroinflammation in Huntington's disease. J Neural Transm (Vienna) (2010) 1.16
Huntingtin in health and disease. J Clin Invest (2003) 1.14
A cellular perspective on conformational disease: the role of genetic background and proteostasis networks. Curr Opin Struct Biol (2010) 1.13
The elimination of accumulated and aggregated proteins: a role for aggrephagy in neurodegeneration. Neurobiol Dis (2010) 1.12
Somatic mosaicism of expanded CAG repeats in brains of patients with dentatorubral-pallidoluysian atrophy: cellular population-dependent dynamics of mitotic instability. Am J Hum Genet (1996) 1.10
Proteasome activator enhances survival of Huntington's disease neuronal model cells. PLoS One (2007) 1.10
Targeting several CAG expansion diseases by a single antisense oligonucleotide. PLoS One (2011) 1.08
RNA-mediated toxicity in neurodegenerative disease. Mol Cell Neurosci (2012) 1.07
Repeat associated non-ATG (RAN) translation: new starts in microsatellite expansion disorders. Curr Opin Genet Dev (2014) 1.06
Full-length huntingtin levels modulate body weight by influencing insulin-like growth factor 1 expression. Hum Mol Genet (2010) 1.06
Huntingtin-associated protein (HAP1): discrete neuronal localizations in the brain resemble those of neuronal nitric oxide synthase. Proc Natl Acad Sci U S A (1996) 1.05
The role of the immune system in Huntington's disease. Clin Dev Immunol (2013) 1.03
An upstream open reading frame impedes translation of the huntingtin gene. Nucleic Acids Res (2002) 1.03
Neurodegenerative processes in Huntington's disease. Cell Death Dis (2011) 1.03
Expansion of polyglutamine repeat in huntingtin leads to abnormal protein interactions involving calmodulin. Proc Natl Acad Sci U S A (1996) 1.03
Corticostriatal dysfunction and glutamate transporter 1 (GLT1) in Huntington's disease: interactions between neurons and astrocytes. Basal Ganglia (2012) 1.02
pARIS-htt: an optimised expression platform to study huntingtin reveals functional domains required for vesicular trafficking. Mol Brain (2010) 1.00
Huntington's disease and the striatal medium spiny neuron: cell-autonomous and non-cell-autonomous mechanisms of disease. Neurotherapeutics (2012) 0.98
Huntingtin-interacting proteins, HIP14 and HIP14L, mediate dual functions, palmitoyl acyltransferase and Mg2+ transport. J Biol Chem (2008) 0.98
Genetic and pharmacological inhibition of calcineurin corrects the BDNF transport defect in Huntington's disease. Mol Brain (2009) 0.96
Using advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease. NeuroRx (2004) 0.96
Skeletal muscle pathology in Huntington's disease. Front Physiol (2014) 0.94
Errors in Huntington disease diagnostic test caused by trinucleotide deletion in the IT15 gene. Am J Hum Genet (1996) 0.92
Neuroprotection for Huntington's disease: ready, set, slow. Neurotherapeutics (2008) 0.92
Proteomic analysis of wild-type and mutant huntingtin-associated proteins in mouse brains identifies unique interactions and involvement in protein synthesis. J Biol Chem (2012) 0.92
The Huntington disease protein accelerates breast tumour development and metastasis through ErbB2/HER2 signalling. EMBO Mol Med (2013) 0.91
Gain of glutamines, gain of function? Nat Genet (1995) 0.91
CAG trinucleotide RNA repeats interact with RNA-binding proteins. Am J Hum Genet (1996) 0.90
Huntingtin promotes cell survival by preventing Pak2 cleavage. J Cell Sci (2009) 0.87
Transgenic models of Huntington's disease. Philos Trans R Soc Lond B Biol Sci (1999) 0.87
Are there multiple pathways in the pathogenesis of Huntington's disease? Philos Trans R Soc Lond B Biol Sci (1999) 0.87
Identification and localization of a neuron-specific isoform of TAF1 in rat brain: implications for neuropathology of DYT3 dystonia. Neuroscience (2011) 0.87
Glutamine repeats as polar zippers: their role in inherited neurodegenerative disease. Mol Med (1995) 0.85
Huntingtin gene evolution in Chordata and its peculiar features in the ascidian Ciona genus. BMC Genomics (2006) 0.85
Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington Disease. PLoS Curr (2010) 0.85
Comparative study of naturally occurring huntingtin fragments in Drosophila points to exon 1 as the most pathogenic species in Huntington's disease. Hum Mol Genet (2014) 0.84
Polyglutamine Disease Modeling: Epitope Based Screen for Homologous Recombination using CRISPR/Cas9 System. PLoS Curr (2014) 0.84
Monomeric, oligomeric and polymeric proteins in huntington disease and other diseases of polyglutamine expansion. Brain Sci (2014) 0.84
Huntingtin localisation studies - a technical review. PLoS Curr (2011) 0.82
Activated microglia proliferate at neurites of mutant huntingtin-expressing neurons. Neurobiol Aging (2011) 0.81
Protein kinase C beta II mRNA levels decrease in the striatum and cortex of transgenic Huntington's disease mice. J Psychiatry Neurosci (2001) 0.81
Altered Ca(2+) signaling in skeletal muscle fibers of the R6/2 mouse, a model of Huntington's disease. J Gen Physiol (2014) 0.80
Huntingtin interacts with the receptor sorting family protein GASP2. J Neural Transm (Vienna) (2006) 0.80
Obsessive-Compulsive Disorder Symptoms in Huntington's Disease: A Case Report. Rev Colomb Psiquiatr (2008) 0.79
Aggregation of expanded huntingtin in the brains of patients with Huntington disease. Prion (2009) 0.79
The localization and interactions of huntingtin. Philos Trans R Soc Lond B Biol Sci (1999) 0.78
Huntington disease: advances in molecular and cell biology. J Inherit Metab Dis (1997) 0.77
Huntington's disease (HD): degeneration of select nuclei, widespread occurrence of neuronal nuclear and axonal inclusions in the brainstem. Brain Pathol (2014) 0.77
Impaired TrkB Signaling Underlies Reduced BDNF-Mediated Trophic Support of Striatal Neurons in the R6/2 Mouse Model of Huntington's Disease. Front Cell Neurosci (2016) 0.76
Molecular Imaging Markers to Track Huntington's Disease Pathology. Front Neurol (2017) 0.75
Fast-to-Slow Transition of Skeletal Muscle Contractile Function and Corresponding Changes in Myosin Heavy and Light Chain Formation in the R6/2 Mouse Model of Huntington's Disease. PLoS One (2016) 0.75
Polyglutamine Tract Expansion Increases S-Nitrosylation of Huntingtin and Ataxin-1. PLoS One (2016) 0.75
HTRF analysis of soluble huntingtin in PHAROS PBMCs. Neurology (2013) 0.75
Novel Metabolic Abnormalities in the Tricarboxylic Acid Cycle in Peripheral Cells From Huntington's Disease Patients. PLoS One (2016) 0.75
Structure of a single-chain Fv bound to the 17 N-terminal residues of huntingtin provides insights into pathogenic amyloid formation and suppression. J Mol Biol (2015) 0.75
Of mice and men: solving the molecular mysteries of Huntington's disease. J Anat (2000) 0.75
Xyloketal-derived small molecules show protective effect by decreasing mutant Huntingtin protein aggregates in Caenorhabditis elegans model of Huntington's disease. Drug Des Devel Ther (2016) 0.75
Age-associated chromatin relaxation is enhanced in Huntington's disease mice. Aging (Albany NY) (2017) 0.75
Huntington's disease blood and brain show a common gene expression pattern and share an immune signature with Alzheimer's disease. Sci Rep (2017) 0.75
Increased irritability, anxiety, and immune reactivity in transgenic Huntington's disease monkeys. Brain Behav Immun (2016) 0.75
Mutant huntingtin is secreted via a late endosomal/lysosomal unconventional secretory pathway. J Neurosci (2017) 0.75
Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (1996) 11.59
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP international workshop. Neurology (1996) 8.82
Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome. Science (1991) 7.16
Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell (1998) 7.13
Ovalbumin gene is split in chicken DNA. Nature (1977) 7.05
Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med (1996) 6.57
Neurostimulation for Parkinson's disease with early motor complications. N Engl J Med (2013) 6.37
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial. BMJ (1999) 5.36
Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet (2004) 5.06
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature (1993) 5.05
Association between early-onset Parkinson's disease and mutations in the parkin gene. N Engl J Med (2000) 4.98
DNA methylation: organ specific variations in the methylation pattern within and around ovalbumin and other chicken genes. Nucleic Acids Res (1979) 4.81
Transient acute depression induced by high-frequency deep-brain stimulation. N Engl J Med (1999) 4.79
The N-terminal part of TIF1, a putative mediator of the ligand-dependent activation function (AF-2) of nuclear receptors, is fused to B-raf in the oncogenic protein T18. EMBO J (1995) 4.72
The FMR-1 protein is cytoplasmic, most abundant in neurons and appears normal in carriers of a fragile X premutation. Nat Genet (1993) 4.57
Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain (2005) 4.33
The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Brain (1999) 4.25
Genetic mapping of the human X chromosome by using restriction fragment length polymorphisms. Proc Natl Acad Sci U S A (1984) 4.22
Alpha-amanitin: a specific inhibitor of one of two DNA-pendent RNA polymerase activities from calf thymus. Biochem Biophys Res Commun (1970) 4.16
The ovalbumin gene family: structure of the X gene and evolution of duplicated split genes. Cell (1980) 4.14
RANTES deposition by platelets triggers monocyte arrest on inflamed and atherosclerotic endothelium. Circulation (2001) 3.86
Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol Histopathol (1997) 3.80
Intranuclear inclusions of expanded polyglutamine protein in spinocerebellar ataxia type 3. Neuron (1997) 3.73
A gene mutated in X-linked myotubular myopathy defines a new putative tyrosine phosphatase family conserved in yeast. Nat Genet (1996) 3.67
Human TAFII30 is present in a distinct TFIID complex and is required for transcriptional activation by the estrogen receptor. Cell (1994) 3.46
The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif. EMBO J (2001) 3.42
Behavioural disorders, Parkinson's disease and subthalamic stimulation. J Neurol Neurosurg Psychiatry (2002) 3.41
Report of the committee on the genetic constitution of the X chromosome. Cytogenet Cell Genet (1989) 3.37
Cloning of the gene for spinocerebellar ataxia 2 reveals a locus with high sensitivity to expanded CAG/glutamine repeats. Nat Genet (1996) 3.26
Mutations in the kinase Rsk-2 associated with Coffin-Lowry syndrome. Nature (1996) 3.21
The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity. Genes Dev (1999) 3.17
Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum Mol Genet (1997) 3.11
Prenatal diagnosis and carrier detection of Duchenne muscular dystrophy with closely linked RFLPs. Lancet (1985) 3.08
Polyglutamine expansion as a pathological epitope in Huntington's disease and four dominant cerebellar ataxias. Nature (1995) 2.92
The ovalbumin gene family: hormonal control of X and Y gene transcription and mRNA accumulation. Cell (1981) 2.91
Neurosurgery at an earlier stage of Parkinson disease: a randomized, controlled trial. Neurology (2006) 2.90
The telomeric region of the human X chromosome long arm: presence of a highly polymorphic DNA marker and analysis of recombination frequency. Proc Natl Acad Sci U S A (1985) 2.88
Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion. Nat Genet (1997) 2.77
Origin of the expansion mutation in myotonic dystrophy. Nat Genet (1993) 2.70
Report of the Committee on Human Gene Mapping by Recombinant DNA Techniques. Cytogenet Cell Genet (1985) 2.70
Monogenic causes of X-linked mental retardation. Nat Rev Genet (2001) 2.68
Distinct TFIID complexes mediate the effect of different transcriptional activators. EMBO J (1993) 2.66
Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol (1994) 2.65
Organization of coding and intervening sequences in the chicken ovalbumin split gene. Cell (1978) 2.61
DNA probe localization at 18p113 band by in situ hybridization and identification of a small supernumerary chromosome. Hum Genet (1985) 2.59
Neurosurgery in Parkinson disease: a distressed mind in a repaired body? Neurology (2006) 2.59
Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain (1991) 2.52
Partially overlapping neural networks for real and imagined hand movements. Cereb Cortex (2000) 2.47
Characterization of a premeiotic germ cell-specific cytoplasmic protein encoded by Stra8, a novel retinoic acid-responsive gene. J Cell Biol (1996) 2.46
Isolation and characterization of cDNA clones for human skeletal muscle alpha actin. Nucleic Acids Res (1983) 2.45
Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J Neurochem (1989) 2.44
hTAF(II)68, a novel RNA/ssDNA-binding protein with homology to the pro-oncoproteins TLS/FUS and EWS is associated with both TFIID and RNA polymerase II. EMBO J (1996) 2.42
The ovalbumin gene region: common features in the organisation of three genes expressed in chicken oviduct under hormonal control. Nature (1979) 2.35
DNA methylation: correlation with DNase I sensitivity of chicken ovalbumin and conalbumin chromatin. Nucleic Acids Res (1979) 2.31
Adenovirus as an expression vector in muscle cells in vivo. Proc Natl Acad Sci U S A (1992) 2.30
PMLRAR homodimers: distinct DNA binding properties and heteromeric interactions with RXR. EMBO J (1993) 2.29
The mental representation of hand movements after parietal cortex damage. Science (1996) 2.28
Close linkage of fragile X-mental retardation syndrome to haemophilia B and transmission through a normal male. Nature (1984) 2.28
Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J Neurochem (1989) 2.26
The chemokine KC, but not monocyte chemoattractant protein-1, triggers monocyte arrest on early atherosclerotic endothelium. J Clin Invest (2001) 2.26
Bilateral subthalamic stimulation for Parkinson's disease by using three-dimensional stereotactic magnetic resonance imaging and electrophysiological guidance. J Neurosurg (2000) 2.25
Human xeroderma pigmentosum group D gene encodes a DNA helicase. Nature (1993) 2.25
Regional localization on the human X chromosome and polymorphism of the coagulation factor IX gene (hemophilia B locus). Proc Natl Acad Sci U S A (1984) 2.23
Rapid antibody test for fragile X syndrome. Lancet (1995) 2.22
Two distinct nuclear receptor interaction domains in NSD1, a novel SET protein that exhibits characteristics of both corepressors and coactivators. EMBO J (1998) 2.20
Frequency of the DYT1 mutation in primary torsion dystonia without family history. Arch Neurol (2000) 2.17
A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displaying selective interactions with FMRP-related proteins FXR1P and FXR2P. Proc Natl Acad Sci U S A (2001) 2.17
Abnormal pattern detected in fragile-X patients by pulsed-field gel electrophoresis. Nature (1991) 2.13
The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther (2001) 2.10
Friedreich ataxia in Louisiana Acadians: demonstration of a founder effect by analysis of microsatellite-generated extended haplotypes. Am J Hum Genet (1992) 2.10
Neuroinflammatory processes in Parkinson's disease. Ann Neurol (2003) 2.10
Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow up. J Neurol Neurosurg Psychiatry (2005) 2.08
Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology (2000) 2.08
Carrier detection of Hemophilia B by using a restriction site polymorphism associated with the coagulation Factor IX gene. J Clin Invest (1984) 2.07
Nitric oxide synthase and neuronal vulnerability in Parkinson's disease. Neuroscience (1996) 2.06
Ataxia with isolated vitamin E deficiency is caused by mutations in the alpha-tocopherol transfer protein. Nat Genet (1995) 2.03
Friedreich's ataxia: point mutations and clinical presentation of compound heterozygotes. Ann Neurol (1999) 2.02